Delving into the Latest Updates on Nedaplatin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(glycolato-O,O')diammineplatinum(II), CDGP, Nedaplatin (JAN/INN)

+ [11]

Target

DNA

Mechanism

DNA inhibitors(DNA inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [2]

Active Indication

NeoplasmsBladder CancerEsophageal Carcinoma+ [6]

Inactive Indication-

Originator Organization

Nichi-Iko Pharmaceutical Co., Ltd.

Active Organization

Nichi-Iko Pharmaceutical Co., Ltd.Simcere Zaiming Pharmaceutical Co., Ltd.

Shionogi & Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (30 Jun 1995),

Bladder CancerEsophageal CarcinomaHead and Neck Neoplasms+ [5]

RegulationOrphan Drug (US)

Login to view timeline

Structure/Sequence

Molecular FormulaC2H8N2O3Pt

InChIKeyGYAVMUDJCHAASE-UHFFFAOYSA-M

CAS Registry95734-82-0

This study is a prospective, open-label, multi-center phase III study; patients with untreated stage IIIA to stage IVB head and neck squamous cell carcinoma (including oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, and laryngeal cancer) who meet the inclusion criteria are randomized 1:1 and given pembrolizumab 200 mg d1+ chemotherapy for 2 cycles (experimental group), 2 cycles of chemotherapy (control group), and then stratified according to the patient's condition. If the imaging evaluation after neoadjuvant treatment is (complete response, CR), adjuvant radiotherapy will be given; if the imaging evaluation is (partial response, PR) or (stable disease, SD), surgery (within 2 weeks) will be performed, followed by standard treatment. The main research hypothesis of this study: pembrolizumab combined with standard chemotherapy can significantly improve the rate of pathological complete response (pCR) compared with standard chemotherapy.

Start Date01 May 2023

Sponsor / Collaborator

Beijing Tongren Hospital

100 Clinical Results associated with Nedaplatin

Login to view more data

100 Translational Medicine associated with Nedaplatin

Login to view more data

100 Patents (Medical) associated with Nedaplatin

Login to view more data

1,033

Literatures (Medical) associated with Nedaplatin

01 Jan 2025·Journal of Gastroenterology

Definitive-dose adjuvant radiotherapy following endoscopic submucosal dissection for superficial esophageal cancer

Article

Author: Murata, Toshiki ; Watanabe, Kenta ; Shinozaki, Tetsugaku ; Iijima, Katsunori ; Sugawara, Daichi ; Mori, Naoko ; Takagi, Noriko ; Wada, Yuki ; Kumagai, Satoshi ; Matsuhashi, Tamotsu

BACKGROUNDProphylactic chemoradiation therapy (CRT) using 40-41.4 Gy post-endoscopic submucosal dissection (ESD) for clinical T1N0M0 esophageal cancer reportedly yields favorable outcomes. However, it cannot completely prevent locoregional lymph node (LN) metastases. We retrospectively analyzed outcomes and adverse events associated with our dose-escalated treatment regimen (definitive-dose radiotherapy [RT] of 50-61.2 Gy, with/without chemotherapy) for these patients, and predictors of progression-free survival (PFS) and overall survival (OS).METHODSBetween 2006 and 2018, 44 consecutive patients (42 men and 2 women; median age, 70 years) who underwent definitive-dose RT post-ESD and had a pathological depth of the muscularis mucosa with lymphovascular invasion (LVI) or the upper-middle submucosal third at our institution were included. We excluded patients who could not obtain a margin-free resection by ESD. If feasible, systemic chemotherapy with 5-fluorouracil plus high- or low-dose cisplatin or nedaplatin was administered concurrently.RESULTSFive-year PFS, OS, and disease-specific survival rates were 78.8%, 88.4%, and 97.7%, respectively. Six metachronous esophagus (14%), two locoregional LN within the irradiated area with a prophylactic dose of 41.4 Gy (5%), and two locoregional LN plus liver (5%) recurrences occurred. No LN recurrence occurred within the definitive dose of ≥ 50 Gy in the irradiated area. Metachronous esophageal recurrence involved areas receiving ≥ 50 Gy. Univariate and multivariate analyses revealed that age was an independent prognostic factor for both PFS and OS.CONCLUSIONSDefinitive-dose RT/CRT post-ESD could provide favorable locoregional LN control and PFS/OS regardless of patient characteristics, including pathological findings and chemotherapy regimen/course, except for age. These results need to be interpreted carefully given several limitations, therefore, definitive-dose RT/CRT should be conducted with caution in clinical practice until high-quality prospective clinical trials evaluating the effectiveness and safety.

18 Nov 2024·Alternative therapies in health and medicine

Specific Efficacy and Safety in the Clinical Application of Anlotinib for Thymic Carcinoma.

Article

Author: He, Jianbo ; Zeng, Aiping ; Liu, Qianfei ; Ning, Ruiling

BackgroundThymic carcinoma is a rare and aggressive malignancy characterized by high invasiveness, poor prognosis, and limited treatment options post-chemotherapy failure. Anlotinib, a novel tyrosine kinase inhibitor, has shown promise in inhibiting tumor growth and metastasis, suggesting potential as an adjunctive therapy in this challenging clinical setting.ObjectiveTo evaluate the efficacy and safety of Anlotinib as a potential treatment option for thymic carcinoma post-chemotherapy failure, assessing its impact on tumor progression and patient survival outcomes.Case PresentationA 46-year-old female presented with a left supraclavicular mass persisting for one month. Percutaneous needle biopsy of the left mediastinal mass confirmed thymic carcinoma, specifically lowly differentiated squamous cell carcinoma.ManagementThe patient underwent sequential treatment modalities, including first-line therapy, comprising four cycles of cisplatin + paclitaxel, followed by subsequent radiotherapy to the chest and neck. It was followed by second-line therapy involving six cycles of cyclophosphamide + pirarubicin + nedaplatin and third-line therapy consisting of four cycles of gemcitabine and nedaplatin. Notably, fourth-line therapy with Anlotinib monotherapy resulted in a progression-free survival of 10 months.OutcomeAnlotinib emerges as a potential therapeutic option for thymic carcinoma post-chemotherapy failure. However, further validation through preclinical investigations and clinical trials is warranted.ConclusionDespite its limited ability to rapidly reduce tumor size, Anlotinib demonstrates efficacy in inhibiting neovascularization and impeding tumor progression and metastasis, thereby maintaining long-term tumor stability. It highlights its potential as a valuable adjunctive therapy in the management of thymic carcinoma.

15 Nov 2024·Medicine

Neoadjuvant chemo-radiotherapy combined with immune checkpoint inhibitors: A case report of rectal small-cell undifferentiated carcinoma achieved pathological complete response

Article

Author: Zhou, Chaoxi ; Liu, Ming ; Xiao, Yuting ; Wu, Fengpeng ; Gao, Chao ; Xiao, Linlin ; Gao, Yuanhang ; Wang, Yi ; Wang, Xuan ; Qu, Fuyin

Rationale:Small-cell undifferentiated carcinoma (SmCC), as an aggressive malignancy, are most commonly arising in lung. Extrapulmonary SmCC is rare. It was reported that SmCC accounts for only 0.1% to 0.2% of colorectal cancers. Currently, no standard treatment regimen is recommended. Here, we presented a case of SmCC from rectum. The patient achieved pathological complete response (pCR) after surgery, which makes us feel gratified, and we are also eager to share this successful case with more peers to provide more references for clinical decision-making.Patient concerns:A 32-year-old male patient presented himself to our outpatient clinic with defecation difficulty for more than 1 month in November 2021.Diagnoses:Colonoscopy revealed a rectal mass 4 cm from the anal margin. Pelvic magnetic resonance imaging revealed a mass in the rectal wall, consistent with the appearance of rectal carcinoma. Cancer cell was found after several biopsies and the immunohistochemistry indicated rectal SmCC.Interventions:Considering that the patient is very young and the malignancy of SmCC is very high, our treatment plan is also very cautious. Many literatures were also searched, but the literature on rectal SmCC is few and the prognosis is poor. Subsequently, we combined the treatment principles of rectal cancer and small cell lung cancer to develop an individualized treatment plan for patients. The patient received neoadjuvant chemoradiotherapy (nCRT) (short-course radiotherapy: 25 Gy/5 fractions, chemotherapy: etoposide + nedaplatin) combined with immune checkpoint inhibitors (ICIs) (tislelizumab). Then, the patient received laparoscopic radical transabdominal resection of rectal carcinoma with a temporary stoma on June 27, 2022.Outcomes:Postoperative pathology showed that there was chronic inflammation in the rectal mucosa without residual cancer, which meant that the patient achieved pCR after nCRT combined with ICIs. On August 15, 2024, the patient returned to our hospital for review, and no signs of recurrence and metastasis were found. By the time this article is submitted, the patient has survived for more than 35 months.Lessons:This is the first to be reported in a rectal SmCC patient who achieved pCR after nCRT combined with ICIs, which may provide supporting data for using this treatment option for rectal SmCC.

100 Deals associated with Nedaplatin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01416	Nedaplatin	L01XA	DB13145

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Neoplasms	JP	Shionogi & Co., Ltd.	05 Sep 1995
Bladder Cancer	JP	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1995
Esophageal Carcinoma	JP	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1995
Head and Neck Neoplasms	JP	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1995
Non-Small Cell Lung Cancer	JP	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1995
Ovarian Cancer	JP	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1995
Small Cell Lung Cancer	JP	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1995
Testicular Neoplasms	JP	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1995
Uterine Cervical Cancer	JP	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1995

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04834206 (ASCO 12023 \| ASCO 22023) Manual	Phase 2	Nasopharyngeal Carcinoma First line	32	intensity-modulated radiotherapy+nedaplatin+docetaxel+5-fluorouracil	(zqzmtpkkol) = lsagjdxzsp iuqenesbca (suxtlvjixz ) View more	Positive	31 May 2023
ChiCTR2100049693 (ASCO 12023 \| ASCO 22023) Manual	Phase 2	Esophageal Carcinoma Neoadjuvant	27	anlotinib+tislelizumab+paclitaxel liposome+nedaplatin	(imxahxwjgg) = xqupmunyxq jkuuunqgfh (xhereeyykn, 61 - 94.5)	-	31 May 2023
ESMO_IO2022	Not Applicable	Advanced Esophageal Squamous Cell Carcinoma First line	35	Pembrolizumab + Albumin-bound paclitaxel + Nedaplatin	(edmkovvjus) = 3 patients (8.6%) ehscacooiu (cgfzilpemt )	Positive	08 Dec 2022
ChiCTR1800017108 (Pubmed) Manual	Phase 3	Uterine Cervical Cancer	160	radiotherapy+Nedaplatin	(alcqlgsdmn) = bpqiujyfol hprowgykqe (qjjpbvmwpv ) View more	Non-inferior	19 Aug 2022
ChiCTR1800017108 (Pubmed) Manual	Phase 3	Uterine Cervical Cancer	160	radiotherapy+Cisplatin	(alcqlgsdmn) = zktqeuljpc hprowgykqe (qjjpbvmwpv ) View more	Non-inferior	19 Aug 2022
NCT02607592 (NACA, ASCO2022) Manual	Phase 3	Advanced Lung Adenocarcinoma First line EGFR Negative \| ALK Negative	218	Pemetrexed+Nedaplatin	(hvsjzxobbf) = kskmnkavwg qngfpfyrbx (zsjdcosgnd, 5.25 - 8.49) View more	Non-inferior	02 Jun 2022
NCT02607592 (NACA, ASCO2022) Manual	Phase 3		218	Pemetrexed+Cisplatin	(hvsjzxobbf) = ctiaqmbqvu qngfpfyrbx (zsjdcosgnd, 4.57 - 6.50) View more	Non-inferior	02 Jun 2022
NCT03057106 (CCTG BR34 \| CCTG BR.34, CTgov)	Phase 2	Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	301	Tremelimumab+Durvalumab (Durvalumab and Tremelimumab)	(zfrtixrrpc) = yqaiajwhrc oclpymwxuj (thdycybxij, jbvyznjcnb - ewxmxribak) View more	-	09 Feb 2022
NCT03057106 (CCTG BR34 \| CCTG BR.34, CTgov)	Phase 2	Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	301	Tremelimumab+Lobaplatin+Cisplatin,+Durvalumab+Nedaplatin (Platinum Based Chemotherapy + Durvalumab + Tremelimumab)	(zfrtixrrpc) = mxyzrdphws oclpymwxuj (thdycybxij, sajksgvnde - dkboacvyos) View more	-	09 Feb 2022
ChiCTR2100046355 (ESMO_IO2021)	Phase 2	Locally Advanced Esophageal Squamous Cell Carcinoma First line	86	Camrelizumab + Paclitaxel + Nedaplatin	(edabxsipyz) = nljwkxzcdy wcwddzmrin (zpfpsfxnyb ) View more	-	09 Dec 2021
ChiCTR2100046355 (SITC 12021 \| SITC 22021) Manual	Phase 2	Esophageal Squamous Cell Carcinoma First line	83	paclitaxel+nedaplatin+Camrelizumab	(cxfdheqkfu) = reduction of redblood cell (21%), anemia (18%), hypomagnesemia (18%), fatigue(14%), thrombocytopenia (11%), hand-foot skin reaction (8.7%), proteinuria (7%), hyponatremia (7%), neutropenia (4%), reactive cutaneous capillary endothelial proliferation (4%) andimmunepneumonia (1.4%). lnlosadswl (trxvkxnsvg )	Positive	25 Sep 2021
ESPRIT (CSCO2021)	Not Applicable	Locally Advanced Esophageal Squamous Cell Carcinoma Neoadjuvant	34	Camrelizumab + Paclitaxel + Nedaplatin	(ohmcsmrfvm) = ppxexpvhbm kqeugidrje (jlsutnnhce ) View more	-	25 Sep 2021
CSCO2021	Not Applicable	Locally Advanced Esophageal Squamous Cell Carcinoma First line	77	Camrelizumab + Paclitaxel + Nedaplatin	(vjbbkwfcyo) = qnwzloyupa ktszguzgxw (rhqvldwndt ) View more	-	25 Sep 2021